Amina T.

Focuses on innovative treatments for acute leukemias and lymphoid neoplasms.

• Frontline incorporation of blinatumomab in Acute Lymphoblastic Leukemia
• Targeted therapy for Acute Myeloid Leukemia with NPM1‑mut or KMT2A‑r
• Bispecific antibodies and CAR‑T approaches in relapsed Diffuse Large B‑Cell Lymphoma

Efforts aim to improve remission depth and long‑term survival.

Addresses disease mechanisms and outcomes in chronic kidney and vascular disorders.

• Low‑dose anticoagulation to reduce major adverse cardiovascular events in advanced Chronic Kidney Disease
• Diuretic‑based algorithms for uncontrolled hypertension in renal impairment
• Evaluation of novel agents for proteinuric kidney disease

Research integrates cardiology and nephrology perspectives.

Explores immunomodulatory approaches for systemic and renal autoimmunity.

• Therapeutic withdrawal strategies in ANCA‑associated vasculitis
• Targeted treatment of Sjögren’s syndrome with moderate‑to‑severe activity
• Interventions for systemic lupus erythematosus renal involvement

Goals include reducing disease flares while preserving organ function.

Develops precision therapies for cancers driven by specific genetic alterations.

• KRAS‑directed inhibitors in KRAS G12C‑mutated lung cancer
• BRAF‑targeted combinations for BRAFV600E‑mutant tumors
• HER2‑focused agents in HER2‑mutated non‑small cell lung cancer

Efforts align with emerging biomarker‑driven treatment paradigms.